Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning with sigma receptor ligands and expanding to other drugs from screening in the field, we became concerned that phospholipidosis was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tummino, Tia A., Rezelj, Veronica V., Fischer, Benoit, Fischer, Audrey, O’Meara, Matthew J., Monel, Blandine, Vallet, Thomas, White, Kris M., Zhang, Ziyang, Alon, Assaf, Schadt, Heiko, O’Donnell, Henry R., Lyu, Jiankun, Rosales, Romel, McGovern, Briana L., Rathnasinghe, Raveen, Jangra, Sonia, Schotsaert, Michael, Galarneau, Jean-René, Krogan, Nevan J., Urban, Laszlo, Shokat, Kevan M., Kruse, Andrew C., García-Sastre, Adolfo, Schwartz, Olivier, Moretti, Francesca, Vignuzzi, Marco, Pognan, Francois, Shoichet, Brian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501941/
https://www.ncbi.nlm.nih.gov/pubmed/34326236
http://dx.doi.org/10.1126/science.abi4708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501941/
https://www.ncbi.nlm.nih.gov/pubmed/34326236
http://dx.doi.org/10.1126/science.abi4708

Ejemplares similares